Quantum Leap Healthcare Collaborative: Market Research Report

Background

Overview

Quantum Leap Healthcare Collaborative (QLHC) is a 501(c)(3) nonprofit organization established in 2005 through a partnership between medical researchers at the University of California, San Francisco, and Silicon Valley entrepreneurs. The organization focuses on integrating high-impact clinical research with advanced healthcare technology to enhance patient outcomes and improve clinical trial accessibility.

Mission and Vision

QLHC's mission is to better serve patients by accelerating and innovating healthcare through approaches that challenge the status quo of science and care. Their vision is to improve human health for all through personalized medicine by bridging the gap between research and care.

Primary Area of Focus

QLHC specializes in adaptive, biomarker-driven oncology platform trials, aiming to evaluate investigational agents and combinations across molecularly defined patient subgroups. They also focus on integrating electronic health records (EHRs) with research data capture to streamline clinical data entry and sharing.

Industry Significance

As a nonprofit organization, QLHC plays a pivotal role in bridging the gap between academic research and clinical application, facilitating the rapid translation of scientific discoveries into patient care. Their innovative approach to clinical trial design and execution has set new standards in oncology research.

Key Strategic Focus

Core Objectives

Accelerate the development of personalized medicine by integrating research with clinical processes.

Enhance patient access to clinical trials through innovative matching systems.

Improve data management and information systems to support clinical research.

Specific Areas of Specialization

Adaptive oncology trial platforms.

Biomarker-driven trial design and implementation.

Clinical data integration with EHR systems.

Key Technologies Utilized

Adaptive randomization algorithms.

RNA-based liquid biopsy assays.

AI-driven biomarker analytics.

Electronic data capture (EDC) systems with EHR integration.

Remote patient monitoring platforms.

Primary Markets or Conditions Targeted

QLHC primarily targets oncology, focusing on breast cancer, and aims to expand personalized trial matching to all cancers and diseases to support clinical trial participation for all patients.

Financials and Funding

Funding History

As a nonprofit organization, QLHC's funding primarily comes from contributions, program services, and investment income. In the fiscal year ending December 2024, they reported revenue of $45.5 million and expenses of $62.6 million, resulting in a net loss of $17 million. The total assets were $40.2 million, with liabilities of $28.8 million, leading to net assets of $11.4 million.

Notable Investors

As a nonprofit entity, QLHC does not have traditional investors. Instead, they receive funding from philanthropic organizations, government grants, and partnerships with industry stakeholders.

Intended Utilization of Capital

The capital is utilized to support the development and implementation of innovative clinical trials, enhance data management systems, and expand patient access to clinical trials. This includes funding for adaptive oncology trials, integration of EHRs with research data capture, and patient engagement programs.

Pipeline Development

Key Pipeline Candidates

I-SPY 2.2 Trial: An adaptive platform trial evaluating the efficacy of investigational agents in early-stage breast cancer patients.

RECAST DCIS Phase 2 Platform Study: A Phase 2 study aiming to evaluate alternative, less invasive treatments for ductal carcinoma in situ to reduce progression to invasive breast cancer.

Stages of Clinical Trials or Product Development